The RemeOs Spinal Interbody Cage aims to re-establish the height between vertebrae and promote fusion within the cervical spine. Credit: Olena Yakobchuk/ Shutterstock.

Bioretec has announced an acceleration in the development of the RemeOs Spinal Interbody Cage, a medical device that is set to innovate spinal surgery with its MRI-compatible, absorbable hybrid composite technology.

This strategic decision follows the device’s receipt of the breakthrough device designation from the US Food and Drug Administration in March 2024.

This approval has led the company to re-evaluate its product development timeline and financial strategy, considering the device’s potential impact on spinal surgery technology.

The RemeOs Spinal Interbody Cage is designed to restore intervertebral height and facilitate fusion in the cervical spine. It stands out for its use of a magnesium alloy, which has earned patents in both the US (US11969519B1) and Europe (EP3782657B1).

It aims to overcome the limitations of traditional implants by reducing complications and improving patient outcomes.

See Also:

The results from initial simulations and technological proofs of concept have established a strong commercial rationale for the acceleration of the RemeOs Spinal Interbody Cage’s development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The feedback from medical experts has been positive, highlighting the device’s potential applications and benefits.

With an estimated market potential of approximately €2.3bn ($2.5bn) by 2028 for the RemeOs Spinal Interbody Cage and €8.1bn for related hybrid composite applications, Bioretec is positioning itself for a significant commercial opportunity.

The device’s properties are expected to enhance bone growth and reduce stress shielding complications.

To align with the revised product development strategy, Bioretec’s board of directors has updated the company’s financial targets.

Bioretec is exploring various financing options and has appointed Danske Bank, Finland Branch, as its financial advisor to support these efforts.